Announcing an upcoming Online event on Tuesday 25th February 2025 at 3pm
HER2 IHC Interpretation Masterclass
Tuesday 25th February 2025 3pm
ONLINE EVENT
AstraZeneca and Daiichi Sankyo are pleased to invite you to join a masterclass on interpreting HER2 immunohistochemistry (IHC) based on the internationally recognised American Society of Clinical Oncology (ASCO) & College of American Pathologists (CAP) guidelines. The masterclass will focus on the interpretation of HER2 0 and 1+ IHC expression in breast cancer and is aimed at practicing and trainee pathologists working in the field.
Accurate assessment of low levels of HER2 expression has become important for clinical decision-making in breast cancer and for ensuring patients with metastatic disease have access to appropriate care. Complexities in this process include accurate quantification of HER2 staining intensity, membranous vs cytoplasmic staining as well as considerations around sample quality and assay selection.
The masterclass will address these and other challenges facing pathologists assessing HER2 IHC. A set of sample cases will be made available in advance of the session.
The masterclass itself will be provided by Professor Grace Callagy. A digital platform, Pathomation, will be used to conduct the training with VENTANA anti-HER2/neu (4B5) assay images. The masterclass will comprise of a mix of a lecture, practical anonymous assessments of challenging cases with low levels of HER2 expression and discussion around these cases.
The 90 minute webinar will include:
· An overview of low level HER2 expression and its clinical importance
· A close look at the practicalities and challenges of interpreting low
level HER2 expression
· A guided review of examples cases
· Your own anonymous assessment of cases and discussion
We do hope you will be able to join us and look forward to seeing you at the masterclass.
If you are interested in attending the webinar please reach out to the Diagnostics Manager (AstraZeneca), Dr Dawn Baynes @ dawn.baynes@astrazeneca.com for registration.
This is a non-promotional medical education masterclass organised and funded by AstraZeneca and Daiichi Sankyo. The ISSP have had no involvement in this masterclass.
Comments